Exodus Point Capital Management, LP Adverum Biotechnologies, Inc. Transaction History

Exodus Point Capital Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 19, 2022	SELL	$0.81 - $1.34 $321,053 - $531,125	-396,362 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$1.23 - $1.95 $96,631 - $153,195	78,562 Added 24.72%	396,362 $519,000
Q4 2021 Feb 11, 2022	SELL	$1.74 - $2.4 $286,861 - $395,671	-164,863 Reduced 34.16%	317,800 $559,000
Q3 2021 Nov 15, 2021	BUY	$2.08 - $3.6 $926,845 - $1.6 Million	445,599 Added 1202.24%	482,663 $1.05 Million
Q2 2021 Aug 16, 2021	BUY	$3.36 - $10.56 $124,535 - $391,395	37,064 New	37,064 $130,000

Q1 2021 May 17, 2021	SELL	$9.26 - $14.36 $112,157 - $173,928	-12,112 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$9.84 - $14.26 $119,182 - $172,717	12,112 New	12,112 $131,000
Q3 2020 Nov 16, 2020	SELL	$10.3 - $21.64 $106,955 - $224,709	-10,384 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$8.53 - $25.64 $88,575 - $266,245	10,384 New	10,384 $217,000

3.6M

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $684M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.